|
Re: patients in clinical trial overwhelmingly prefer subcutaneous herceptin administr
Such debates in their intricate and lengthy considerations always cause me to wonder just how many bc patients don't make it due to drug administration problems and/or because we aren't permitted to find out whether there are patients who get equal benefit from administration of
trastuzumab w/o chemo
trastuzumab w/o chemo plus ovarian ablation
trastuzumab w/o chemo plus tamoxifen (+/- ovarian ablation)
trastuzumab w/o chemo plus an AI (+/- ovarian ablation)
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|